FDA Proposes PDUFA VIII and GDUFA IV Changes for 2028-2032

Key Takeaways

• The US Food and Drug Administration’s (FDA) proposed Prescription Drug User Fee Act (PDUFA) VIII and Generic Drug User Fee Amendments (GDUFA) IV agreements establish performance goals and program enhancements for prescription and generic drug reviews for fiscal years 2028 through 2032.
• PDUFA VIII emphasizes first-cycle review efficiency, sponsor communication, rare disease development, and modernized regulatory approaches.
• GDUFA IV aims to improve review predictability, reduce abbreviated new drug applications (ANDA) assessment cycles, and facilitate timely access to generic medicines.

The FDA has released proposed commitment letters outlining performance goals and program changes for the next iterations of the PDUFA and GDUFA, setting the stage for congressional reauthorization before the current programs expire in 2027.

The proposals, which would cover fiscal years (FYs) 2028 through 2032, address drug review timelines, FDA-sponsor communication, generic drug development, regulatory science, domestic research and manufacturing, and agency staffing and resources.^1-4

What are PDUFA and GDUFA?

PDUFA and GDUFA establish user fee programs that help fund FDA activities related to the review of prescription and generic drug applications, respectively. The agreements also establish performance goals intended to promote timely reviews and greater predictability and transparency in the regulatory process.^3,4

The proposed PDUFA VIII and GDUFA IV commitment letters were developed through discussions among FDA, regulated industry, and public stakeholders. The FDA will consider additional public input before transmitting formal recommendations to Congress. Congress must enact legislation to reauthorize the programs before the current authorization expires September 30, 2027.^1,2,4

PDUFA VIII Maintains Core Drug Review Timelines

Under the proposed PDUFA VIII agreement, the FDA would generally retain existing performance goals for new drug applications (NDAs), biologics license applications (BLAs), and manufacturing supplements.^1,3

The FDA would continue to aim to review and act on 90% of standard new molecular entity NDAs and original BLAs within 10 months of the 60-day filing date and 90% of priority applications within 6 months.¹ The agency would also maintain performance goals for resubmissions, efficacy supplements, and manufacturing supplements.

One major focus of PDUFA VIII is improving communication between the FDA and sponsors during the first review cycle. Beginning October 1, 2027, the FDA proposes an enhanced review transparency and communication program for new molecular entity NDAs and original BLAs. The program is intended to improve the efficiency of first-cycle reviews and reduce the number of review cycles required before approval.^1,4

The FDA also proposes an independent third-party assessment of its first-cycle review processes and sponsor communications. The review would examine opportunities to reduce complete response actions, missed deadlines, review extensions, and communication challenges.^3,4

New Incentives Target US Drug Development

PDUFA VIII also includes proposed financial incentives aimed at encouraging US-based clinical research. According to the Regulatory Affairs Professionals Society, the FDA is recommending a 50% reduction in application fees for qualifying submissions that include clinical data from at least one phase 1 trial conducted in the US and initiated after October 1, 2027.³

Other proposed changes include allowing sponsors developing products across multiple therapeutic areas to request coordinated meetings with multiple FDA review divisions and incorporating programs involving rare disease endpoints, complex innovative trial designs, and real-world evidence into FDA's formal meeting framework.^1,3

For rare diseases, the FDA would continue integrating specialized staff into review teams and supporting flexible approaches to clinical development. The agency also proposes Rare Disease Innovation, Science, and Exploration workshops to address scientific and drug development challenges.¹

GDUFA IV Focuses on Generic Drug Review Efficiency

The proposed GDUFA IV agreement similarly emphasizes greater efficiency and predictability. The FDA states that the enhancements are intended to maximize the usefulness of each assessment cycle, reduce the number of cycles needed for ANDAs, and facilitate timely access to generic medicines.²

The FDA aims to assess and act on 90% of standard original ANDAs within 10 months. Priority ANDAs could have an 8-month goal when applicants meet specified pre-submission facility correspondence requirements; otherwise, the goal would generally be 10 months.²

GDUFA IV would also reorganize formal meetings into Type 30, Type 60, Type 90, and Type 120 categories, with different purposes and timelines based on the regulatory issue involved.⁴

Additional proposals include enhanced ANDA communications, updates to the Inactive Ingredient Database, creation of a public database containing maximum daily dose information, changes related to inspections and facilities, and initiatives supporting complex generic drugs and domestic manufacturing.^2,4

Why It Matters for Managed Care

Although PDUFA and GDUFA primarily govern FDA-industry interactions, the programs can have downstream implications for payers and other managed care stakeholders because they influence the regulatory processes through which new therapies, biologics, and generic competitors reach the market.

PDUFA VIII's emphasis on first-cycle review efficiency, regulatory communication, rare disease development, and modernized regulatory approaches could affect how efficiently new therapies move through FDA review. Meanwhile, GDUFA IV's focus on reducing assessment cycles and supporting generic drug approvals may be particularly relevant to stakeholders monitoring generic competition and pharmaceutical spending.^1,2

However, the proposals remain subject to change. The FDA has scheduled public meetings for September 16, 2026, for PDUFA and September 17, 2026, for GDUFA. Written comments are due October 16 and October 17, respectively. The FDA will consider stakeholder feedback before sending the formal commitment letters to Congress.⁴

The Bottom Line

The proposed PDUFA VIII and GDUFA IV agreements outline the FDA's priorities for prescription and generic drug review from FY 2028 through FY 2032, with a common emphasis on regulatory efficiency, communication, transparency, and timely review. For managed care stakeholders, the reauthorization process bears watching because changes affecting new drug development and generic competition could ultimately influence the therapies entering the market and the timing of their availability.

References

1. US Food and Drug Administration. PDUFA reauthorization performance goals and procedures fiscal years 2028 through 2032. Proposed PDUFA VIII Commitment Letter. 2026. Accessed August 21, 2026. https://www.fda.gov/media/193977/download
2. US Food and Drug Administration. GDUFA reauthorization performance goals and program enhancements fiscal years 2028-2032. Proposed GDUFA IV Commitment Letter. 2026. Accessed August 21, 2026. https://www.fda.gov/media/194166/download
3. Eglovitch JS. PDUFA VIII: FDA outlines goals, program enhancements in commitment letter. Regulatory Affairs Professionals Society. August 13, 2026. Accessed August 21, 2026. https://www.raps.org/resource/pdufa-viii-fda-outlines-goals-program-enhancements-in-commitment-letter.html
4. Brossi JK, Werner MJ, Klock SM. FDA releases draft GDUFA, PDUFA commitment letters as user fee reauthorizations move forward. Holland & Knight.  August 18, 2026. Accessed August 21, 2026. https://www.hklaw.com/en/insights/publications/2026/08/fda-releases-draft-gdufa-pdufa-commitment-letters-as-user-fee